Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MarrowMimi

Financiado

Cerrado

A bone marrow mimicry bioreactor for cost effective production of hematopoietic...

A bone marrow mimicry bioreactor for cost effective production of hematopoietic stem cells Hematopoietic stem/progenitor cell (HSPC) therapies have the potential to treat over 70 diseases including blood cancers and leukemia and are one of only 22 advanced therapy medicinal products currently approved by the European Me... ver más

31/08/2027

TU/e

203K€

Presupuesto del proyecto: 203K€

Líder del proyecto

TECHNISCHE UNIVERSITEIT EINDHOVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-21

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TU/e

203.46K€ | Lider

Proyectos interesantes

POSEIDON

Medical Technol...

Biotechnology

159K€ Cerrado

NOVEXPAND

Medical Technol...

Biotechnology

181K€ Cerrado

REDONTAP

Medical Technol...

Biotechnology

4M€ Cerrado

REACH

Medical Technol...

Biotechnology

7M€ Cerrado

STEMCELL2MAX

Medical Technol...

Data Science

164K€ Cerrado

HSCORIGIN

Medical Technol...

Biotechnology

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 39 meses Fecha Inicio: 2024-05-21
Fecha Fin: 2027-08-31

Líder del proyecto

TECHNISCHE UNIVERSITEIT EINDHOVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 203K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hematopoietic stem/progenitor cell (HSPC) therapies have the potential to treat over 70 diseases including blood cancers and leukemia and are one of only 22 advanced therapy medicinal products currently approved by the European Medicines Agency. However, the number of HSPCs derived from a single blood donation can be insufficient for modern therapies, which typically require a minimum of 10^7 cells. To service adequate treatment regimes, HSPCs must be expanded in the laboratory at great financial expense, resulting in exorbitant treatment costs of up to €315,000. New methods of ex vivo HSPC expansion are therefore required to reduce production costs and ensure therapy affordability. The industry standard for HSPC expansion utilises liquid suspension bioreactors, where cells are diluted in litres of culture media to a final concentration of only 10^3-5 cells/mL. This liquid media, containing large amounts of expensive nutrients, provides high cell expansion but results in high production costs. Liquid suspension bioreactors vary significantly from how humans grow HSPCs within high-cell-density tissue (10^8-11 cells/mL), which require only a fraction of the nutrient quantities per-cell. The bone marrow is the human body’s natural HSPC bioreactor and provides a defined microenvironment for optimal cell production. I aim to artificially replicate these niche conditions by creating a marrow mimicry bioreactor (MarrowMimi) to maximise ex vivo HSPC expansion by (1) formulating a hydrogel scaffold to mimic the bone marrow extracellular matrix, (2) utilising state-of-the-art 3D printing technologies to create a marrow-like perfusion bioreactor, and (3) optimising reaction conditions to maximise HSPC expansion and minimise nutrient demand. The ability to minimise HSPC expansion-associated costs could ensure lifesaving therapies are more widely available to the community, therefore, MarrowMimi will focus on optimising methods for cost effective ex vivo HSPC production.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores